Daniquidone

N/A

Report date: 2022/05/18 17:41:58
NME

Base Information

Drug NameDaniquidone
Drug Alias Name达尼喹酮BatracylinBay-h-2049NSC-320846
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTopoisomerase II inhibitorsDNA topoisomerase I inhibitors
TargetsTopoisomerase IIDNA topoisomerase I
Therapy Area/IndicationsLymphomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBayer AG
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer InstituteBayer AG
Active IndicationsN/A
Inactive IndicationsLymphomaNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A